{"id":9286,"date":"2020-06-10T15:08:26","date_gmt":"2020-06-10T19:08:26","guid":{"rendered":"https:\/\/ufluidix.com\/circle\/?p=9286"},"modified":"2020-06-10T16:25:52","modified_gmt":"2020-06-10T20:25:52","slug":"microfluidics-and-approval-bottlenecks-in-a-pandemic","status":"publish","type":"post","link":"https:\/\/www.ufluidix.com\/circle\/microfluidics-and-approval-bottlenecks-in-a-pandemic\/","title":{"rendered":"Microfluidics and Approval Bottlenecks in a Pandemic"},"content":{"rendered":"

Minimizing harm to patients from inadequately-tested new pharmaceuticals \u2014 and the bankroll-boggling process of adequate testing \u2014 are grabbing pandemic headlines. \u201cThe pharmaceutical industry needs new ways of doing things<\/a>\u201d is one example.<\/p>\n

Microfluidics<\/a> advances have hovered on the horizon as a \u201cnew way\u201d for some time. The creation and development of new drugs can cost millions, yet many end up being recalled for toxicity, or just plain not as effective in humans as they are in lab animals.<\/p>\n

The authors of a 2019 statistical analysis, \u201cImpact of organ-on-a-chip technology on pharmaceutical R&D costs<\/a>,\u201d describe how high drug prices are driven by the huge expense of creating new product. They report that 60-75 percent of new drugs that succeed in non-human phases fail in later phases. \u201cBetter predictive models are needed,\u201d they concluded, in something of an understatement.<\/p>\n

Better predictive models include microfluidic platforms called organs-on-a-chip<\/a>. These platforms are engineered to improve on the prognostic capacity of animal or in vitro models \u2014 which too often inaccurately simulate human physiology. As controlled microenvironments with vasculature perfusion that mimic the structure and function of human tissue, organ-a-chip technology has the potential to decrease the conventional roadblock of extensive development time frames, and their choking costs.<\/p>\n

Although actual expenditures of private pharmaceutical companies are not made public, the statistical analysts estimate the potential of microfluidics to reduce R&D costs at 10-25 percent. The authors granularly analyzed some development costs by phase. They concluded that organ-on-a-chip technology could significantly reduce R&D costs by reducing the length of the early-stage research process.<\/p>\n

The analysts note that, \u201cExperts believed that the technology will help to make quicker and more precise decisions\u201d during initial stages of research. One analyst said that if organ-on-chip was capable of identifying appropriate biomarkers, it would become the \u201cHoly Grail\u201d of biotechnology.<\/p>\n

The authors do not pretend change arrives astride a fast horse. \u201cThe extent to which organ-on-a-chip can evolve in terms of predictability and applicability to the human biophysiology is yet to be seen,\u201d they write. \u201cChallenges of automation, parallelization, standardization and ease of use remain.\u201d<\/p>\n

Concerns driving the current conversation among experts focus on the magnitude of transformation. The tradition of utilizing in vitro and animal models is deeply ingrained and rooted, to state one obvious funding barrier. Results anticipated by innovators and early adopters can \u201ctake much longer to materialize when meeting the skepticism of the late majority and laggards.\u201d<\/p>\n

Not only are microfluidic devices pushing for legitimacy in the minds of some, but the very methods used to create them are often never-before-seen tools butting up against history as well. 3D bioprinting comes to mind.<\/p>\n

There are pre-publication<\/a> reports concerning vascularized micro-tissues for many major organs. For example, micro-tissued pancreatic islets have potential for insulin regulation and insulinomas. Liver buds are being researched. There has been progress in bioprinting vascularized thyroid glands.<\/p>\n

In addition, genome engineering techniques may create genetic disease models using microfluidic platforms. Personalized medicine applications may include drug screening for patient-specific tumors.<\/p>\n

In their study titled \u201cLong-term Expanding Human Airway Organoids for Disease Modeling<\/a>,\u201d lung specialists wrote that \u201chuman airway organoids represent versatile models for the\u00a0in vitro\u00a0study of hereditary, malignant, and infectious pulmonary disease.\u201d<\/p>\n

The world certainly does have an \u201cinfectious pulmonary disease\u201d on board.<\/p>\n

Can regulatory shibboleths and personal proclivities accommodate the pace of innovation? Despite the complexity of research, the degree of potential is climbing. According to a recent Research and Markets<\/em><\/a> report, microfluidics technology is replicating many functions of traditional healthcare, including clinical diagnostics, point-of-care diagnostics and drug delivery: \u201cThe global microfluidics market size is projected to reach USD 44.0 billion by 2025 from USD 15.7 billion in 2020.\u201d<\/p>\n

One research team recently<\/a> described why \u201cfrontier technological tools by which infections are studied and new drugs and vaccines are tested\u201d include \u201cmicrofluidic chambers for the culture of organoids.\u201d Given they are Milan, Italy-based, this team comprises COVID-19 experts.<\/p>\n

The pandemic-weary world awaits \u201cfrontier tools.\u201d<\/p>\n

 <\/p>\n

Enjoyed this article? Don\u2019t forget to share.<\/strong><\/em><\/p>\n

<\/i>Love<\/span>0<\/span><\/span><\/a> <\/i>